ClinicalTrials.gg
Not yet recruitingNCT07017465Updated Jun 12, 2025

Determination of the Glycemic Index (GI) and Glycemic Load (GL) of Watermelon (Citrullus Lanatus) in Healthy Adults

An interventional study of Water melon (sugar baby) and watermelon (Charleston gray) in Glycemic Index and Glycemic Load, sponsored by Rehman Medical Institute - RMI. Not yet recruiting. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Rehman Medical Institute - RMI · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 30 Years
Sex
All
01

Study summary

This study aims to evaluate and compare the glycemic load (GL) and glycemic index (GI) of different types of watermelons commonly available in the market. Using glucose as the reference standard, the study will measure the blood glucose response following consumption of each watermelon type in healthy adult participants.

Read the detailed description

his study aims to evaluate and compare the glycemic load (GL) and glycemic index (GI) of different types of watermelons commonly available in the market. Using glucose as the reference standard, the study will measure the blood glucose response following consumption of each watermelon type in healthy adult participants. The objective is to identify variations in glycemic impact among watermelon varieties to inform dietary recommendations for blood sugar management.

02

Conditions studied

  • Glycemic Index
  • Glycemic Load

Keywords

  • GLYCEMIC INDEX
03

In context

Lead sponsor

Rehman Medical Institute - RMI is the lead sponsor of 24 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:•

  1. Healthy adults ( 18.5-24.9kg/m2.
  2. No history of diabetes or metabolic disorders.
  3. Not taking any medication affecting glucose metabolism.

Exclusion Criteria:

  1. GI Disorders. 2) Recent infections or illness affecting glucose tolerance. 3) Non willing participants.

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Single group (cross over)

    Participants will consume a standard oral glucose solution containing 50 grams of available carbohydrate. This serves as the reference for calculating glycemic index.

    Other: Water melon (sugar baby) · Other: watermelon (Charleston gray) · Other: watermelon (Crimson sweet)

Interventions

  • OtherWater melon (sugar baby)

    Participants will consume a portion of watermelon Type A containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.

  • Otherwatermelon (Charleston gray)

    Participants will consume a portion of watermelon Type B containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.

  • Otherwatermelon (Crimson sweet)

    Participants will consume a portion of watermelon Type C containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.

06

What researchers measure

Primary outcomes

  1. Glycemic Index (GI) of Watermelon Varieties

    Description: Incremental area under the blood glucose response curve (iAUC) over 120 minutes after consuming each watermelon type, expressed as a percentage of the iAUC after consuming the glucose reference.

    Time frame: 1 month

Secondary outcomes

  1. Glycemic Load (GL) of Watermelon Varieties

    Calculated using the formula: Glycemic Load = (GI × carbohydrate content per typical serving) ÷ 100

    Time frame: 1 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • A. Coughlan , E. Anderson , L. Stern , A. El-Ansary , in: Marketing Channels, Prentice Hall, New Jersey, 2001, p. 590p .
  • R. Clodius , W. Mueller , Market structure analysis, an orientation for research in agricultural economics, J. Farm Econ. 43 (3) (1961) 513-553 .
  • A. Camelo , in: Manuel Pour La Préparation Et La Vente Des Fruits Et Des Légumes Du Champ Au Marché, Bulletin des Services Agricoles de la FAO. FAO, Rome, 2007, p. 205 p .
  • I. Adeoye , T. Olajide , A. Adebisi , J. Usman , M. Badmus , Economic analysis of watermel on based production system in Oyo state, J. Agric. Biol. Sci. 6 (7) (2011) 53-59 .
  • E.G. Achigan-Dako , R. Fagbemissi , H.T. Avohou , R.S. Vodouhe , O. Coulibaly , A. Ahanchede , Importance and practices of Egusi crops (Citrullus lanatus (Thunb.) Matsum. & Nakai, Cucumeropsis mannii Naudin and Lagenaria siceraria (Molina) Standl. cv. ' Aklamkpa ') in sociolinguistic areas in Benin, Biotechnol. Agron. Soc. Environ. 12 (4) (2008) 393-403 .
  • I.A. Abdou , Modified marketing efficiency criteria for consideration in cropping structure planning: a case of newly reclaimed land farmers in Egypt, in: S. O'reilly, M. Keane, P. Enright (Eds.), Proceedings of the 16th international farm management association congress, a vibrant rural economy-the challenge for balance, Cork Ireland, 2007, pp. 79-84

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Aug 2025, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jun 12, 2025
StartEst.
Jun 2025
Primary completionEst.
Aug 2025
CompletionEst.
Sep 2025
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07017465
Lead sponsor
Rehman Medical Institute - RMI
Responsible party
Naseer Ahmed (Associate Professor, Rehman Medical Institute - RMI) — Principal investigator
First posted
Jun 12, 2025
Start date
Jun 2025 (estimated)
Primary completion
Aug 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Jun 12, 2025

Study contacts

Naseer Ahmed
Contact
dr.naseer99@mail.com
03305485960

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion